Testing effectiveness (Phase 2)Study completedNCT03861793
What this trial is testing
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Who this might be right for
Advanced Solid Tumors
Mural Oncology, Inc 116